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Comparative genomic hybridization (CGH) is a powerful tool
for genome-wide screening of tumours for copy number
changes of DNA sequences (Kallioniemi et al, 1992).
Application of CGH and fluorescence in situ hybridization
(FISH) to primary tumours of prostatic adenocarcinomas
revealed consistent changes on chromosomes 7, 8p, 10, 13q, 16,
17 and 18q (Brothman et al, 1994; Macoska et al, 1994;
Matsuyama et al, 1994; Joos et al, 1995; Qian et al, 1995;
Visakorpi et al, 1995; Bova and Isaacs, 1996; Cher et al, 1996;
Huang et al, 1996; Deubler et al, 1997). However, cytogenetic
changes in prostatic intraepithelial neoplasias (PIN) which are
considered as premalignant lesions and which are often present
besides the invasive tumour are only poorly characterized cyto-
genetically (Alers et al, 1995; Qian et al, 1995; Zitzelsberger
et al, 1998). Methodological improvements of approaches
combining microdissection and CGH analysis (Kuukasjärvi et
al, 1997) were prerequisites for the analysis of such early chro-
mosomal aberrations in premalignant cells of other tumours like
cervical carcinoma (Heselmeyer et al, 1996), breast cancer
(Aubele et al, 2000b) and oral malignant lesions (Weber et al,
1998). Their application to premaligant lesions in prostate
cancer has recently been described (Zitzelsberger et al, 1998;
Kim et al, 1999), but for an improved understanding of mecha-
nisms of tumour development and tumour progression more
data on cytogenetic changes in thePIN–adenocarcinoma–metas-
tasis sequence are needed. 
The present study reports on the results of CGH analysis in
16 prostatic adenocarcinomas, 12 related PINs and 5 lymph
node metastases. These investigations are aimed at a delineation
of chromosome copy number changes in the non-neoplastic
prostatic gland–PIN–invasive carcinoma–metastasis sequence. 
MATERIAL AND METHODS 
Tissue samples 
Formalin-fixed and paraffin-embedded tissue specimens of
16 adenocarcinomas of the prostate and of 5 related lymph
node metastases were analysed. 12 intraepithelial neoplasias
(4 low-grade and 8 high-grade PINs) adjacent to the primary
tumours and non-neoplastic prostatic glands from 3 cases
were additionally investigated. The histological classification
and grading were performed on H&E-stained sections (Gleason
and Mellinger, 1974; Sobin and Wittekind, 1997).
Pathohistological data of cases are summarized in Table 1.
Serial 5 mm sections of the tissue blocks were used for microdis-
section of tissue samples. For FISH analysis, consecutive 10 mm
sections were analysed. Non-neoplastic glands, PINs and metas-
tases were laser-microdissected and genomic DNA was ampli-
fied by DOP-PCR. DNA of extended areas of primary tumours
was isolated from manually microdissected sections which
provided sufficient DNA amounts for CGH without prior DOP
amplification. 
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For microdissection, a laser microscope system (P.A.L.M., Wolfrats-
hausen, Germany) was used consisting of a Zeiss Axiovert micro-
scope (Zeiss, Jena, Germany), a pulsed UV-laser (wavelength
337 nm, maximum frequency: 20 pulses per second, pulse
duration: 3 nanoseconds), and a computer-controlled micromanipu-
lator. By means of the focussed UV-laser, unwanted cells or tissue
areas, surrounding the cells of interest, were destroyed. Isolated cell
compartments of 50 to 100 cells were subsequently collected. The
cells were transferred into a sterile PCR reaction tube containing 20
ml laser buffer (100 mM Tris/HCl, pH 7.5, 100 mg ml–1 proteinase
K). Microdissected probes were then heated for 3 h at 55˚C to allow
proteolytic digestion and for 8 minutes at 100˚C to inactivate the
proteinase K. Samples were stored at –20˚C until use. 
DOP-PCR 
DOP-PCR was performed according to a published procedure
(Weber et al, 1998; Zitzelsberger et al, 1998). PCR reaction was
carried out in a 50 ml reaction volume (3.5 mM MgCl2, 50 mM KCl,
20 mM Tris/HCl, pH 8.4) containing the microdissected
and pretreated cells in 20 ml laser buffer, 0.2 mM primer UW4B 
(5’-CCGACTCGAGNNNNNNATGTGG-3 ’), and 4 units Taq
polymerase. After 40 PCR cycles (initial step for 10 minutes at
94˚C, 5 cycles with a low annealing temperature at 30˚C, 35 cycles
with a high annealing temperature at 62˚C and a final extension
step), the size of DNA fragments and DNA yields of each reaction
were checked by agarose gel electrophoresis. DNA yields were
additionally determined by fluorimetric measurements. To avoid
contamination of PCR reactions, they were set up in a laminar flow
using special aerosol resistant tips. PCR solutions were additionally
checked for possible contaminations in PCR reactions without
template DNA using gene-specific primers. 
DNA extraction from paraffin-embedded tissue sections 
For primary tumours, CGH was performed from paraffin-
embedded tissue sections. The DNA was extracted according to
standard procedures. 
DNA labelling 
Isolated whole genomic tumour DNA and DOP-PCR amplified
samples were labelled with biotin-16-dUTP by standard nick transla-
tion. As reference DNA, SpectrumRed direct-labelled normal male
total human genomic DNA (Vysis Inc, Downers Grove, IL) was used. 
CGH and image analysis 
Metaphase preparations for CGH analyses were obtained from
peripheral lymphocytes of a healthy male donor according to
standard procedures. CGH analysis was performed according
to Kallioniemi et al (1992) and du Manoir et al (1993) with modifca-
tions. 600 ng of biotin-16-dUTP labelled DNA and 600 ng of
SpectrumRed direct-labelled normal male DNA were simultaneously
hybridized with 25 mg unlabelled Cot-1 DNA (Life Technologies
Inc, Grand Island, NY) to denatured lymphocyte metaphases for 3
days. Bound biotin-labelled DNA probes were detected by sequential
incubations in Cy2-conjugated streptavidin/biotinylated anti-strepta-
vidin (concentration: 10 mg ml–1 and 5 mg ml–1 in PNM-buffer
consisting of PN-buffer plus 5% non-fat dry milk). Between each
incubation step, slides were washed twice in PN-buffer (0.1 M
sodium phosphate pH 8.0, 0.1% nonidet P-40). To obtain a fluores-
cence banding pattern, slides were stained with 4’,6’-diamidino-2-
phenylindole (DAPI) at a concentration of 0.1 mg ml–1 in antifading
solution. CGH images were captured by a black/white video CCD
camera using on chip integration. The 3 colours were digitized
consecutively with specific single colour filter combinations which
were automatically changed on a Zeiss Axioplan2 microscope. For
processing of captured images, a CGH analysis software from
MetaSystems (MetaSystems, Altlussheim, Germany) was used. For
one CGH analysis, 10 to 15 examples of each chromosome were
measured after DAPI karyotyping of 5 to 10 metaphases. Average
ratio profiles were then calculated after automatically scaling the
profiles of individual homologous chromosomes of the same length.
Average profiles were interpreted according to published criteria
(Kallioniemi et al, 1994; Solinas-Toldo et al, 1996) using statistical
confidence limits based on t-statistics. 
Control experiments 
DOP-PCR amplified DNA obtained from non-neoplastic prostatic
glands with morphologically normal appearing prostatic epithe-
lium was hybridized in 3 cases (Table 1) with non-amplified refer-
ence DNA (SpectrumRed&trade;) to metaphase preparations. In
these experiments no chromsomal changes were detected except
for gains on chromosomes 1p34–36 and 19. Such regions of
frequent artifactual appearance were excluded from further inter-
pretation of data (see discussion). In addition, 4 cases of prostate
carcinoma were comprehensively analysed using both DOP-PCR-
amplified and non-amplified DNA. This comparison shows no
significant differences for chromosomal changes detected by both
methods. For additional control of the DOP-PCR approach
microdissected normal epithelium present in tissues from other
tumour entities like Barrett’s adenocarcinoma (Walch et al, 2000)
and ductal breast carcinoma (Aubele et al, 2000b) was investigated
and revealed also CGH profiles without alterations.
Fluorescence in situ hybridization (FISH) analysis 
FISH analyses with centromere and locus specific probes for 
c-myc (8q24), cyclin D1 (11q13), and HER-2/neu (17q11.2–q12)
were performed to validate the CGH findings. Cases with copy
number changes on chromosomes 8q, 11q, and 17q, known from the
CGH experiments, were selected to validate these changes. Serial
10 mm sections of the tissue blocks were used for FISH analysis.
Areas investigated correspond to those examined by CGH.
Commercially available DNA probe kits were used for c-myc
(Oncor, Gaithersburg, USA) and for centromere 8 (Oncor,
Gaithersburg, USA), cyclin D1/centromere 11 (Vysis, Inc; Downers
Grove; USA) and HER-2/neu/centromere 17 (Vysis, Inc; Downers
Grove; USA). Signals from 150–200 tumour cell nuclei per specimen
were counted using a confocal laser scanning microscope (Zeiss
LSM 510). Nuclei from normal squamous epithelium or lympho-
cytes deposited separately on the same slide were used as controls for
hybridization efficiency and specificity. The criteria established by
Hopman et al (1988) were followed for signal enumeration.
Amplification of the respective gene locus was considered for nuclei
exhibiting at least twice as many locus-specific signals as centromere
signals. More than two locus-specific signals accompanied by the
same elevated number of centromere signals were considered to be
indicative of polysomy. When the proportion of cells with nuclei
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insufficient and therefore repeated. For a detailed description of the
FISH method used as well as for the evaluation by confocal laser
scanning mircoscopy see Aubele et al (1997). 
RESULTS 
A summary of chromosomal imbalances detected in 16 adeno-
carcinomas, 12 PINs and 5 metastases is shown in Figure 1. 3
cases (Table 1) were also investigated for chromosome copy
number changes in non-neoplastic prostatic glands for control;
normal profiles were obtained in each of these samples. 
The average aberration frequency (± SEM) in the 12 PIN areas
was 4.3 ± 1.1. In PIN areas, gains were detected on chromosomes 8q
(42%), 7 (25%), 16p (25%), 17 (25%), 19 (33%), 20 (25%), whereas
losses were found on 13q (25%). Additionally, gains on chromo-
somes Xq (17%), 12q (17%), 15q (17%), 22 (17%), 1p, 4p, 11q (one
case each), as well as losses on chromosomes 4q (17%), 2p, 3p,
3q, 5q, 6q, 8p, 10q, 12q, 18q and the Y chromosome (one case
each) became apparent at lower frequencies. The changes showed
a distinct heterogenic distribution, however, all of them were
detectable in the corresponding primary tumours as well. 
An average of 8.5 ± 0.9 gains and losses was detected in the 16
primary tumours. The following aberrations were identified in at
least 25% of tumours: gains on 1p33–36 (38%), 12q24 (25%),
15q23–24 (25%), 16p12–13 (69%), 17 (50%), 19 (75%), 20 (50%),
22 (56%) and losses on 2q32 (25%), 4q28 (25%), 5q21 (31%), Xq
(25%), 13q22 (56%), 18q21–23 (25%). Losses on 8p and 6q as well
as gains on chromosome 7 and 8q were detected at lower frequen-
cies. However, these aberrations occurred in the corresponding
primary tumours as well as in PINs and/or metastases (Fig. 1). 
The 5 lymph node metastases showed changes affecting the
same chromosomal regions in a similar frequency (mean 7.8 ±
1.2). Common aberrations to primary tumours were gains on chro-
mosomes 9q and of chromosome 16 and loss on chromosome 13q. 
CGH data were exemplary validated on selected cases
(4778/92, 10673/91, 10844/91) using a FISH approach on consec-
utive 10 mm sections and subsequent laser scanning microscopy
(Table 2). Additionally, LOH analysis for D8S137 locus on
chromosome 8p was carried out for validation of 8p loss (Table 2).
To verify chromosomal gains on 8q21–24 (4778/92 carcinoma and
PIN), 11q13 (10673/91 carcinoma and PIN, 10844/91 carcinoma)
and 17 (4778/92 carcinoma), locus-specific probes for c-myc
(8q24), cyclin D1 (11q13) and HER-2/neu (17q11.2–q12) were
applied together with the respective centromere probes. In case
4778/92 an amplification of the c-myc locus could be detected in
carcinoma and PIN areas in addition to polysomy of chromosome
17 in carcinoma areas. Cases 10673/91 (carcinoma and PIN) and
10844/91 carcinoma revealed polysomy of chromosome 11 and
amplification of the cyclin D1 locus in case 10844/91. No locus-
specific amplifications could be detected for the HER-2/neu locus. 
DISCUSSION 
Prostate cancer development and progression is supposed to be
driven by the accumulation of cytogenetic and molecular genetic
alterations. At the histological level, PINs outside the invasive carci-
noma are considered as premalignant lesions of prostate cancer
(Bostwick and Brawer, 1987; Bonkhoff and Remberger, 1996). In
the PIN–carcinoma–metastasis sequence, PIN areas are poorly char-
acterized for chromosomal alterations because they appear as very
small cell compartments which can be only studied utilizing either
microdissection and subsequent molecular genetic techniques like
CGH (Weber et al, 1998; Zitzelsberger et al, 1998; Kim et al, 1999)
or FISH on paraffin sections (Alers et al, 1995; Qian et al, 1996;
Jenkins et al, 1997). In this study, we were able to demonstrate cyto-
genetic changes in 5 lymph node metastases and 12 PIN areas from
6 different cases. Chromosomal imbalances occurring in primary
tumours were basically consistent with changes in PINs and metas-
tases, and affected the same chromosomal regions (Fig. 1). 
Common changes in the PIN–carcinoma–metastasis sequence
became apparent and comprise losses on chromosomes 4q, 5q, 8p,
13q and gains on chromosomes 7, 8q, 12q and 15q. Losses on 2q
and gains on 9/9q were only present in carcinoma and metastasis
specimens and, thus, may indicate late events during tumorigen-
esis. Our data set on chromosomal changes in PIN areas provides
clues that alterations reported as typical changes in prostate cancer
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Table 1 Prostatic adenocarcinomas, PINs and lymph node metastases analysed 
Case Gleason Score pTNM Classificationa Age Tissue lesions analysed 
15075/90 8 T3bN0 65 PT 
635/91 6 T3bN1 64 PT, Met 
5573/91 6 T3b N0 63 PT 
5640/91 5 T3a N0 67 PT 
9350/91 8 T2b N0 52 PT 
14323/91 7 T2b N2 67 Met 
15008/91 7 T3b N1 62 N, PIN high grade (3x), PT, Met 
862/92 9 T4 N0 71 PIN high grade (2x), PT 
1287/92 5 T3a N1 73 PIN low grade, PT, Met 
4778/92 7 T3b N2 82 N, PIN low grade, PIN high grade, PT, Met 
7757/92 4 T3a N0 65 PT 
8039/92 9 T3b N0 66 PT 
8385/93 3 T2a N0 71 N, PIN low grade (2x), PT 
9971/93 8 T2a N0 61 PIN high grade (2x), PT 
10601/93 5 T3a N0 67 PT 
7632/94 5 T2a N0 55 PT 
14624/94 6 T3a N0 70 PT 
aUICC/TNM-Classification (Sobin and Wittekind 1997). N = Non-neoplastic prostatic glands; PIN = Prostatic intraepithelial neoplasia; PT = Primary tumour; 
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Figure 1 Chromosomal gains and losses in 12 prostatic intraepithelial neoplasias (orange), 16 prostatic adenocarcinomas (blue) and 5 lymph node
metastases (yellow). Gains are indicated on the right side, losses on the left side of ideograms (losses on 8p, 13q, gains on 7, 8q) have a very early origin in PIN.
Thus, a subset of PIN areas, irrespective of their differentiation into
low- or high-grade PIN, exhibits a number of aberrations similar to
invasive carcinoma. These CGH findings on PIN areas confirm for
many of the chromosomal alterations earlier studies which investi-
gated corresponding loci either with LOH (Macintosh et al, 1998;
Saric et al, 1999) or FISH analysis (Alers et al, 1995; Qian et al,
1996). These data provide evidence for the biological significance
of PINs and support the assumption that they represent premalig-
nant lesions of prostate cancer. It might be therefore of prognostic
value to survey PIN areas for their chromosomal aberrations. 
The most frequent losses (25–56%) in the primary tumours
were found on 13q22, 5q21, 2q32, 18q21–23, 4q28 and Xq; most
common regions (25–75%) of chromosomal gains were detected
on 12q and 15q (Fig. 1). Frequently observed gains on chromo-
somes 1p, 16p and of whole chromosomes 19 and 22 were not
taken into account for the interpretation of data because they are
known to represent frequently artifactual results in CGH analysis
(Kallioniemi et al, 1994; Lichter et al, 1995; Weber et al, 1998).
Frequently occurring gains of whole chromosomes 16, 17 and 20
reflect the aneuploid karyotype of the tumours. The frequent
finding of gain on chromosome 12q is in good agreement with a
recent publication (Sattler et al, 1999) reporting on frequent copy
number gains in human prostate cancer. Losses on 8p and 6q as
well as gains on 8q and of chromosome 7, which were considered
to be typical aberrations for prostate cancer (for review see Bova
and Isaacs, 1996), were also detected in primary tumours investi-
gated in this study, but at a lower frequency. This fact can be partly
explained by the smaller number of cases in our study compared to
the literature data. The use of laser-ablation of unwanted cells
surrounding the carcinoma area prior to CGH analysis might be a
second reason for the difference between our and published data
because stromal tissue, normal prostatic glands and PIN areas are
removed before DNA extraction with this approach. A third differ-
ence to most of published prostate cancer cases is the fact that the
majority of our cases do not represent advanced stages. Only 5 of
17 cases (29%; Table 1) are metastasizing cancers which might
influence the cytogenetic results. With respect to the reported
extensive genetic heterogeneity in prostate cancers (Qian et al,
1996; Macintosh et al, 1998) it is not surprising that changes
detected in PIN areas coincidentially resemble more to ‘typical’
published aberrations in prostate cancers than the corresponding
primary tumours. Altogether, our findings in primary carcinomas
are confirmatory for losses on 13q, 18q, 5q, 2q and gains on 7, 8q.
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CA = carcinoma. PIN = prostatic intraepithelial neoplasia. CEP = centromeric DNA probe. AL = allelic loss. nd = not determined. * investigation of microsatellite
locus D8S137. 1A gene locus was classified as amplified if there were more than twice locus-specific signals than centromere signals (ratio > 2) per cell
nucleus. More than two locus specific signals accompanied by the same number of centromere signals was considered to be indicative of polysomy of the
respective chromosome (ratio 1:1). #Mean number of signals per cell. CGH profiles: average profiles for chromosomes 8, 11 and 17 are exemplary
demonstrated. Below each idiogram, the respective chromosome number (left) as well as the number of homologous chromosomes included in the calculation
of the profile (right) are indicated. The red/green ratio is displayed as a white line together with thresholds for loss (red line) and gain (green line). Thresholds
are calculated as statistical confidence intervals by the CGH software. 
Table 2 Confirmation of CGH results with FISH and LOH analysis
Representative FISH analysis1 FISH analysis1 FISH analysis1 LOH analysis
CGH findings CEP 8 c-myc CEP 17 HER-2/neu CEP 11 cyclin D1 on 8p*
Case signals per cell# (range) signals per cell# (range) signals per cell# (range)
4778/92 CA +8q21-24, –8p21-23 2.4 (1–3) 5.0 (2–6) 2.3 (1–3) 2.0 (1–3) nd nd AL
4778/92 PIN +8q21-24, –8p21-23 1.9 (1–3) 4.2 (2–4) 1.7 (1–3) 1.9 (1–3) nd nd AL
10673/91 CA +11q13, +17 nd nd 3.8 (2–5) 3.4 (1–4) 3.1 (1–4) 2.9 (1–4) nd
10673/91PIN – nd nd 2.2 (1–3) 1.8 (1–3) 2.2 (1–4) 1.7 (1–4) nd
10844/9 CA +11q13-14, +17 nd nd 3.9 (2–5) 3.6 (1–4) 2.7 (1–4) 3.2 (1–4) ALTumour progression in prostate cancer 207
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In addition to these known hotspots of chromosomal copy number
changes in prostatic adenocarcinoma, a novel region of chromo-
somal loss on 4q could be detected in our subset of cases.
Deletions on 4q are frequent events in other tumour entities such
as lung tumours (Petersen et al, 1997), renal carcinoma (Jiang
et al, 1998), papillary bladder cancer (Simon et al, 1998), and
appear to play a crucial role during aggressive progression of
hepatocellular carcinoma (Piao et al, 1998). It is postulated that
several, yet
unidentified, putative tumour suppressor genes may be located
on 4q (Hammoud et al, 1996). Although for other known altered
chromosomal regions in prostate cancer (8p, 13q, 8q) candidate
tumour suppressor genes and oncogenes have already been identi-
fied (multiple novel genes on the short arm of chromosome 8, RB
gene on 13q14, c-MYC gene on 8q24), the identification of candi-
date genes in further chromosomal regions affected is still in its
initial stage (Bova and Isaacs, 1996). 
In summary, CGH analysis of 16 adenocarcinomas of the
prostate revealed a series of known chromosomal imbalances in
addition to a novel described loss of DNA sequences on chromo-
some 4q. Investigation of related PINs and lymph node metastases
demonstrated an accumulation of chromosomal imbalances dur-
ing cancer development and progression and an early origin of
tumour-specific aberrations in PIN areas. 
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